Aptevo Therapeutics Inc (APVO)

Price$4.72

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-88.92%

Price vs S&P 500 (4W)-5.02%

VGM Score12.63

Market Capitalization$5.88M

All Metrics

Book Value / Share (Quarterly)$9.65

P/TBV (Annual)3.99x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-22.41

Price vs S&P 500 (YTD)-58.10%

Gross Margin (TTM)51.39%

Net Profit Margin (TTM)-222.55%

EPS (TTM)$-197.29

10-Day Avg Trading Volume0.05M

EPS Excl Extra (TTM)$-197.29

EPS (Annual)$-62.63

ROI (Annual)-504.73%

Gross Margin (Annual)51.39%

Net Profit Margin (5Y Avg)-114.17%

Cash / Share (Quarterly)$12.07

ROA (Last FY)-153.93%

EBITD / Share (TTM)$-46.56

ROE (5Y Avg)-609.94%

Operating Margin (TTM)-154.97%

Cash Flow / Share (Annual)$-25.65

P/B Ratio0.51x

P/B Ratio (Quarterly)0.43x

Net Income / Employee (Annual)$-727,300

EV / Revenue (TTM)-0.67x

ROA (TTM)-117.06%

EV / EBITDA (TTM)-1.20x

EPS Incl Extra (Annual)$-62.63

Current Ratio (Annual)3.81x

Quick Ratio (Quarterly)3.23x

3-Month Avg Trading Volume0.05M

52-Week Price Return-94.51%

EV / Free Cash Flow (Annual)-2.00x

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$100.30

P/S Ratio (Annual)1.89x

Asset Turnover (Annual)0.09x

52-Week High$235.98

Operating Margin (5Y Avg)-235.75%

EPS Excl Extra (Annual)$-62.63

Tangible BV CAGR (5Y)-25.04%

26-Week Price Return-81.00%

Quick Ratio (Annual)3.71x

13-Week Price Return-26.93%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.36x

Enterprise Value$-8.64M

Asset Turnover (TTM)0.22x

Book Value / Share Growth (5Y)-36.29%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)7.97x

Pretax Margin (Annual)225.24%

Cash / Share (Annual)$21.67

3-Month Return Std Dev83.65%

Gross Margin (5Y Avg)41.27%

Net Income / Employee (TTM)$-795,600

ROE (Last FY)-504.73%

EPS Basic Excl Extra (Annual)$-62.63

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-197.29

Receivables Turnover (Annual)0.00x

ROI (TTM)-198.50%

P/S Ratio (TTM)0.45x

Pretax Margin (5Y Avg)-269.14%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$100.30

Price vs S&P 500 (52W)-118.88%

Year-to-Date Return-49.95%

5-Day Price Return-9.92%

EPS Normalized (Annual)$-62.63

ROA (5Y Avg)-56.80%

Net Profit Margin (Annual)257.77%

Month-to-Date Return-3.87%

Cash Flow / Share (TTM)$-2.16

EBITD / Share (Annual)$-101.84

Operating Margin (Annual)274.28%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-164.78%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-197.29

P/TBV (Quarterly)3.99x

P/B Ratio (Annual)0.51x

Inventory Turnover (TTM)7.97x

Pretax Margin (TTM)-228.06%

Book Value / Share (Annual)$17.42

Price vs S&P 500 (13W)-35.19%

Beta1.68x

Revenue / Share (TTM)$0.00

ROE (TTM)-198.50%

52-Week Low$3.80

mGradeF

vgmGradeF

Show chart for

Earnings Surprise History

Q1 26-6.41est. -5.71

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
APVOAptevo Therapeutics Inc	—	—	F	$4.72
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Aptevo Therapeutics is a clinical-stage biotechnology company developing immunotherapeutic cancer treatments using its proprietary ADAPTIR platform technology. The company's lead clinical programs include ALG.APV-527 targeting co-stimulatory receptors and CD3xCD123 for acute myelogenous leukemia, with additional preclinical candidates in development. ADAPTIR enables the generation of monospecific, bispecific, and multi-specific antibodies designed to enhance immune response against cancer cells.